Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 signaling
Morin acts as an MMP-9 inhibitor to disrupt EndMT in atherosclerosis by limiting the activation of Notch-1 signaling. This study underscores morin's potential utility in the development of anti-atherosclerotic medication. Please cite this article as: He Y, Qin XX, Liu MW, Sun W. Morin, a matrix metalloproteinase 9 inhibitor, attenuates endothelial-to-mesenchymal transition in atherosclerosis by downregulating Notch-1 Signaling. J Integr Med. 2024; 22(6): 684-696.
Authors
- Yuan He (ORCID: https://orcid.org/0000-0002-1712-0776)
- Wei Sun (ORCID: https://orcid.org/0000-0003-0405-9774)
- Mingwei Liu (ORCID: https://orcid.org/0000-0001-7061-847X)
- Xiao-Xuan Qin
Institutions
- Jiangsu Provincial Hospital of Traditional Chinese Medicine (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Journal of Integrative Medicine
- Published
- 2024-11-01
- DOI
- https://doi.org/10.1016/j.joim.2024.11.002
- Citations
- 8
- Primary Topic
- Protease and Inhibitor Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 2.28